A detailed history of Vivo Capital, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 997,005 shares of DCTH stock, worth $9.66 Million. This represents 1.32% of its overall portfolio holdings.

Number of Shares
997,005
Previous 1,666,746 40.18%
Holding current value
$9.66 Million
Previous $14 Million 35.47%
% of portfolio
1.32%
Previous 2.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.36 - $11.0 $4.93 Million - $7.37 Million
-669,741 Reduced 40.18%
997,005 $9 Million
Q1 2024

Apr 22, 2024

BUY
$3.72 - $5.09 $3.02 Million - $4.13 Million
811,555 Added 94.9%
1,666,746 $7.95 Million
Q4 2023

Feb 06, 2024

SELL
$2.25 - $4.17 $2.25 Million - $4.17 Million
-1,000,000 Reduced 53.9%
855,191 $3.56 Million
Q3 2023

Nov 08, 2023

BUY
$3.12 - $5.85 $2.11 Million - $3.96 Million
676,404 Added 57.38%
1,855,191 $7.51 Million
Q2 2023

Aug 14, 2023

BUY
$5.38 - $7.96 $6.34 Million - $9.38 Million
1,178,787 New
1,178,787 $6.87 Million

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $83.3M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Vivo Capital, LLC Portfolio

Follow Vivo Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vivo Capital, LLC with notifications on news.